somatropin
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Growth Hormone Disorder
Conditions
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Trial Timeline
May 16, 2001 → Nov 18, 2002
NCT ID
NCT01698944About somatropin
somatropin is a approved stage product being developed by Novo Nordisk for Growth Hormone Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT01698944. Target conditions include Growth Hormone Disorder, Adult Growth Hormone Deficiency.
What happened to similar drugs?
7 of 20 similar drugs in Growth Hormone Disorder were approved
Approved (7) Terminated (0) Active (13)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03435627 | Pre-clinical | Completed |
| NCT01927861 | Phase 3 | Completed |
| NCT01778023 | Phase 3 | Completed |
| NCT01435629 | Pre-clinical | Completed |
| NCT01110928 | Pre-clinical | Completed |
| NCT01109017 | Pre-clinical | Completed |
| NCT00934063 | Pre-clinical | Completed |
| NCT00705172 | Pre-clinical | Completed |
| NCT00519844 | Approved | Completed |
| NCT01604161 | Pre-clinical | Completed |
| NCT00184730 | Phase 3 | Completed |
| NCT00184743 | Phase 3 | Completed |
| NCT00557336 | Phase 3 | Completed |
| NCT01580605 | Pre-clinical | Completed |
| NCT01543880 | Pre-clinical | Completed |
| NCT00519558 | Phase 3 | Completed |
| NCT00102817 | Phase 3 | Completed |
| NCT00184652 | Phase 2 | Completed |
| NCT00567385 | Approved | Completed |
| NCT00184756 | Phase 3 | Completed |
Competing Products
20 competing products in Growth Hormone Disorder